A personalised and non-invasive brain stimulation solution for patients with Major Depressive Disorder, to improve patient outcomes for treatment resistant depression. This trial aims to demonstrate that the novel precision accelerated TMS is superior to the current standard of care and will increase the response rate from 40 per cent to 80 per cent in a shorter time frame from six weeks to one week.